VA Portland Health Care System Joins KIYATEC Clinical Trial to Predict Patient-Specific Response to Glioblastoma Drugs Prior to Treatment

VA Portland Health Care System Joins KIYATEC Clinical Trial to Predict Patient-Specific Response to Glioblastoma Drugs Prior to Treatment

GREENVILLE, S.C. – November XX, 2019 – KIYATEC, Inc. today announced that VA Portland Health Care System (VAPORHCS) has joined its 3D-PREDICT U.S. clinical study to validate the company’s test as a patient-specific predictor of response to cancer therapies for glioblastoma patients.

“VAPORHCS serves more than 95,000 Veterans in Oregon and Southwest Washington and we are dedicated to contributing to important clinical research that may not only advance the healthcare of our Veterans but to all people in the U.S. and abroad,” said XX, YY at VAPORHCS. “The VA is one of the nation’s leaders in health research and with cancer being one of the leading causes of death among Veterans, we are honored to take part in this clinical trial to profile patient-specific glioblastoma drug response.”

3D-PREDICT is a prospective, open-label, multi-institutional, non-interventional study to validate KIYATEC’s EV3D platform for clinical use and to investigate the impact on outcomes in patients with advanced cancers, including recurrent high-grade gliomas and patients with both newly diagnosed and recurrent epithelial ovarian cancer. KIYATEC’s EV3D cell culture platform utilizes live cancer cells derived from surgical or biopsy tissue to create a patient specific in vivo-like tumor and immune microenvironment. The tumor and immune microenvironment are used to accurately model and assess responses from both investigational and approved cancer therapies. The study is anticipated to continue through 2020. Details on the trial can be found on

“Glioblastoma is one of the most common forms of malignant brain cancers and notoriously difficult to treat. Spending months waiting to see if treatment is working is simply not an option, and we developed 3D Predict to help set cancer patients on the optimal treatment course at the earliest possible time,” said Matthew Gevaert, CEO of KIYATEC. “We are honored to be working with VAPORHCS and salute the important work and commitment to clinical trials of all VA hospitals in their desire to make a difference in cancer care.”

About KIYATEC, Inc.
KIYATEC leverages its proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company’s Clinical Services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors, in its CLIA-certified laboratory. The company’s Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types.

SCBIZtv is part of the SC Biz News family, serving 100,000 high-level business execs throughout South Carolina. Click for more from SCBIZtv.